Aim: To determine the seroprevalence of hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV) in pregnant women who presented to the pregnancy outpatient clinic at Umraniye Training and Research Hospital between January 1, 2014, and December 31, 2019, and to reveal the distribution of cases by year. Material and method: Hepatitis B surface antigen (HBsAg), hepatitis B surface antigen-antibody (Anti-HBs), hepatitis C virus antibody (Anti-HCV), and HIV antibody (Anti-HIV) results from blood samples taken from pregnant women admitted to our hospital’s pregnancy outpatient clinic were retrospectively scanned. The results of the line immunoassay validation test performed on patients with Anti-HIV reactivity were obtained from hospital records. Results: Anti-HBs values were examined in 11,263 pregnant women, and positive results were found in 3,898 (34.61%). HBsAg values were examined in 55,639 pregnant women, with positive results in 822 (1.48%). Anti-HCV values were examined in 47,990 pregnant women, and the results were positive in 159 (0.33%). Anti-HIV values were examined in 44,107 pregnant women, and the result was found to be reactive in 40 (0.09%). HIV infection was confirmed in 5 pregnant women (0.01%). The seropositivity rates by year between 2014 and 2019 were 26.16%, 28.94%, 32.20%, 34.82%, 39.66%, and 41.73% for Anti-HBs; 1.54%, 1.52%, 1.46%, 1.53%, 1.45%, and 1.36% for HBsAg; 0.25%, 0.40%, 0.32%, 0.39%, 0.29%, and 0.32% for Anti-HCV; and 0%, 0.07%, 0.13%, 0.07%, 0.15%, and 0.17% for Anti-HIV. Conclusion: During the antenatal period, pregnant women should be screened for HBV, HCV and HIV. Early diagnosis and treatment of HCV and HIV in pregnancy is vital to prevent long-term complications of infections and to reduce the transmission from the mother to the infant.